Anonymous1 day ago
A highly divergent SARS-CoV-2 variant designated BA.3.2 — nicknamed "Cicada" for its sudden emergence after years of dormancy — has been detected in at least 23 countries and 29 U.S. states, carrying 70–75 spike protein mutations that substantially reduce vaccine-generated antibody neutralization. While the variant has reached roughly 30% prevalence in parts of Europe and 11% of U.S. cases, early clinical data show no increase in disease severity, and existing antivirals remain effective — raising the question of whether the alarm is proportionate to the actual public health risk.